There were no differences between these groups regarding pre-transplant patient characteristics, CD34+/TNC doses, neutrophil or platelet engraftment, CMV/other infections, relapse, relapse mortality, non-relapse mortality, relapse-free or overall survival. We conclude that assessment of MICA gene polymorphisms in MRD RIC-AHPCT patients may have important implications for predicting GVHD. Those with a MICA dimorphism indicating weak binding affinity (VV) for the NKG2D activating receptor may have less alloreactive recipient immune effector cells that decrease the risk of developing GVHD. Further investigation of this observation with larger study populations is warranted.
No relevant conflicts of interest to declare.
Asterisk with author names denotes non-ASH members.